PharmAthene Email Format

Biotechnology ResearchMaryland, United States51-200 Employees

PharmAthene, Inc. (NYSE MKT: PIP), formed in March 2001, is pursuing its mission to advance the Nation’s health security by developing novel medical solutions that utilize cutting-edge biotechnology to offer improvements in safety, efficacy and cost-effectiveness over current therapies.  

The Company’s strategy focuses on acquiring and developing new, best-in-class products and technologies identified by the United States and other governments as urgent procurement priorities.  Since its inception in 2001, PharmAthene has obtained non-dilutive U.S. government funding commitments in excess of $600 million for the development of its portfolio products.

PharmAthene's portfolio currently includes the following product candidates:

   •  SparVax® - a next generation recombinant protective antigen (rPA) anthrax vaccine

   •  Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

   •  Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection

✕

Access Insights for PharmAthene and Millions of Other Companies

Sign up for full access to PharmAthene information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory